TGA Also Warns That Mounjaro May Reduce Effectiveness of Oral Contraceptives
Last updated: May 2026 | Regulator: Therapeutic Goods Administration (TGA), Australia | Read time: ~10 min
If you are experiencing thoughts of suicide or self-harm, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988. You can also reach the Crisis Text Line by texting HOME to 741741. If you are in immediate danger, call 911 or go to your nearest emergency room.
Australia’s Therapeutic Goods Administration — the TGA, the country’s national medicines regulator — has issued updated safety guidance covering two distinct concerns relating to GLP-1 receptor agonist medications. The first is a precautionary mental health warning covering Ozempic, Wegovy, Mounjaro, Saxenda, Trulicity, and other GLP-1 drugs, advising healthcare providers to monitor patients for depression, suicidal ideation, and mood changes during treatment. The second is a separate warning specific to Mounjaro (tirzepatide), advising that its gastric-slowing mechanism may reduce the absorption and effectiveness of oral contraceptive pills during treatment initiation and dose escalation.
The TGA was explicit that it has not established a causal link between GLP-1 drugs and suicidal behavior — and its independent expert committee concluded the available evidence falls short of proving causation. What the warnings reflect is the TGA’s view that the accumulating volume of adverse event reports is significant enough to warrant precautionary guidance and heightened clinical vigilance, even in the absence of definitive proof. That distinction — between a precautionary regulatory action and a finding of causation — is important for patients, prescribers, and legal professionals to understand clearly.
Australia’s TGA has not concluded that GLP-1 drugs cause suicidal behavior or depression. The warnings are precautionary, based on adverse event signals that regulators believe warrant monitoring — not a confirmed causal finding. This is consistent with the FDA’s January 2026 position, which similarly found no confirmed causal link.
What the TGA Mental Health Warning Covers
The TGA’s mental health guidance applies broadly across the GLP-1 drug class rather than being confined to a single agent or manufacturer. The drugs specifically named in the TGA’s communications include:
- Ozempic (semaglutide injectable — Novo Nordisk) — Type 2 diabetes
- Wegovy (semaglutide injectable, higher dose — Novo Nordisk) — chronic weight management
- Mounjaro (tirzepatide injectable — Eli Lilly) — Type 2 diabetes
- Saxenda (liraglutide injectable — Novo Nordisk) — chronic weight management
- Trulicity (dulaglutide injectable — Eli Lilly) — Type 2 diabetes
The TGA guidance advises healthcare providers prescribing these medications to actively monitor patients for a specific set of psychiatric symptoms during treatment. The monitoring guidance is directed at clinicians rather than patients — it is a prescriber-level advisory, not a direct consumer warning — though patients and caregivers should be aware of the symptoms the TGA identified as warranting attention:
- New or worsening depression
- Suicidal thoughts or ideation
- Unusual or persistent mood changes
- Significant behavioral changes that are new or unexplained
The TGA’s guidance does not recommend discontinuing GLP-1 treatment in patients who develop these symptoms. Rather, it directs clinicians to take psychiatric symptoms seriously as a potential monitoring signal and to make individualized clinical judgments about how to proceed — which may include referral to a mental health professional or, in some cases, reassessment of the patient’s GLP-1 medication.
What the TGA’s Expert Committee Found
The TGA did not arrive at its precautionary guidance without independent expert review. The agency referred the available psychiatric adverse event data to its Advisory Committee on Medicines — an independent expert body that evaluates safety evidence and provides recommendations to the regulator. The committee’s conclusions are the appropriate starting point for understanding what the TGA’s warnings actually say and do not say.
The Causation Question
The Advisory Committee concluded that the available evidence was not strong enough to establish a causal relationship between GLP-1 drugs and suicidal behavior or depression. This is the same conclusion reached by the European Medicines Agency following its 2023 review, and is consistent with the FDA’s January 2026 position. Across three major regulatory jurisdictions — Australia, the European Union, and the United States — independent expert reviews have examined the same class of evidence and reached the same basic finding: the signal is present, but causation has not been confirmed.
Why the Warning Was Issued Anyway
The committee also noted that the complexity of the patient population makes causal analysis genuinely difficult. People who are prescribed GLP-1 drugs — predominantly those with Type 2 diabetes, obesity, or both — already carry meaningfully elevated baseline rates of depression and anxiety compared to the general population. Separating the psychiatric burden of those underlying conditions from any potential medication effect requires careful epidemiological design that the current observational and adverse-event data cannot fully achieve. The committee’s view was that this interpretive complexity, combined with the volume of adverse event reports, was sufficient reason for precautionary clinical guidance even absent a confirmed causal finding.
The Role of Adverse Event Volume
The TGA’s decision to issue guidance was also informed by the raw volume of reports received through its adverse event database. With millions of semaglutide prescriptions issued in Australia, the number of reported psychiatric adverse events — including completed suicides, suicide attempts, suicidal ideation, and self-injurious thoughts — was large enough in absolute terms to prompt formal regulatory attention, even if the event rate relative to the total prescribing population remained low. Post-market safety surveillance is designed to catch exactly this kind of accumulation: events that are individually rare but collectively significant when a drug is used at mass scale.
The International Regulatory Context
The TGA’s action does not occur in isolation. It reflects a broader pattern of international regulatory attention to GLP-1 psychiatric safety that has been developing since late 2023, and it sits within a global web of overlapping safety reviews and monitoring activities that give the Australian warning its full significance.
The key international regulatory milestones on this question include:
- 2023: The European Medicines Agency initiated a formal review of psychiatric adverse events associated with GLP-1 drugs following adverse event reports from multiple member states. The review concluded without confirming causation but recommended continued monitoring and increased prescriber vigilance — an outcome structurally similar to the TGA’s approach.
- January 2026: The U.S. FDA completed its own formal review of GLP-1 drugs and psychiatric risk, concluding that available evidence did not demonstrate an increased risk of suicide, depression, psychosis, irritability, or anxiety. The FDA continues post-market monitoring.
- March 2026: The FDA issued a warning letter to Novo Nordisk for failure to submit certain adverse event reports within the required 15-day window — including a report involving a patient suicide. That action raised separate questions about whether adverse event data flowing from manufacturers to regulators has been complete and timely.
The pattern across these regulatory actions is consistent: multiple independent regulators have reviewed the same body of evidence, declined to confirm causation, and simultaneously declined to declare the question closed. That combination — not confirmed, but also not resolved — is precisely the kind of uncertain safety landscape that sustains ongoing post-market surveillance and ongoing scientific investigation. For a detailed account of the FDA’s parallel actions on GLP-1 safety, including the March 2026 warning letter, see our FDA warning letter page.
Why the Psychiatric Safety Question Is Genuinely Difficult to Resolve
The consistent pattern of regulators finding a signal but not confirming causation reflects genuine methodological challenges in the underlying research — not regulatory indecision or evasion. Understanding those challenges helps explain why this question has remained unresolved across multiple formal reviews by different agencies.
Confounding by the Underlying Conditions
The most fundamental challenge is that the diseases for which GLP-1 drugs are prescribed are themselves strongly associated with depression and psychiatric comorbidity. Patients with Type 2 diabetes have significantly elevated rates of depression compared to those without diabetes. Obesity is similarly associated with higher rates of mood disorders, anxiety, and reduced psychological wellbeing. Any study comparing psychiatric outcomes between GLP-1 drug users and a control population faces the challenge that the two groups are not psychiatrically equivalent at baseline. Even with sophisticated statistical adjustment, residual confounding remains a concern that limits how confident researchers can be in their conclusions.
Rapid Weight Loss and Psychological Adjustment
GLP-1 drugs can produce dramatic and rapid changes in body weight, eating behavior, and the psychological relationship with food. Some clinicians have observed that the psychological adjustment to rapid weight loss — changes in body image, altered social dynamics around eating, loss of food as a coping mechanism — can be challenging for certain patients, particularly those who have used food as an emotional resource over many years. Research on bariatric surgery patients, who also experience rapid significant weight loss, has documented that a subset of patients experience worsened mood or increased psychiatric symptoms in the months following surgery, even as physical health metrics improve. Whether a similar dynamic occurs in some GLP-1 drug users is a plausible hypothesis that warrants investigation independent of any direct pharmacological mechanism.
The Signal Detection Limit
Adverse event reporting systems are designed to detect safety signals, not to measure their absolute frequency or establish causation. When millions of patients are taking a medication, even a very small absolute rate of a serious adverse event — such as suicide — will generate a substantial number of reports in raw terms. Determining whether that number is higher than what would be expected in an equivalent untreated population requires careful epidemiological analysis that voluntary adverse event databases are not well designed to support. This creates an inherent tension: the volume of reports is too large to ignore, but the data structure prevents a definitive answer about what the reports actually mean.
The Mounjaro Contraceptive Warning: What Patients Need to Know
Separate from the psychiatric safety guidance, the TGA issued a specific warning involving Mounjaro (tirzepatide) and oral contraceptive effectiveness. This warning is mechanistically grounded in one of the drug’s primary pharmacological actions and has practical implications for patients of reproductive age using both medications simultaneously.
The Mechanism
Mounjaro, like all GLP-1 drugs, significantly slows gastric emptying — the rate at which the stomach passes its contents into the small intestine. This is one of the drug’s intended therapeutic mechanisms: by slowing gastric emptying, it reduces post-meal blood glucose spikes and prolongs the sensation of fullness that supports reduced caloric intake. The clinical complication is that delayed gastric emptying affects not only food but also orally administered medications. When the stomach is slower to empty, oral medications — including contraceptive pills — may spend more time in the stomach before reaching the small intestine where absorption primarily occurs. The result can be altered absorption kinetics: lower peak drug concentrations, delayed time to peak absorption, and potentially reduced overall bioavailability.
The TGA specified that this concern is most pronounced during two phases of Mounjaro treatment: when the drug is first initiated, before the patient’s gastrointestinal system has adapted to its effects, and after each dose increase, when the gastric-slowing effect is again intensified relative to the prior dose level. These are the periods when the interference with oral contraceptive absorption is considered most clinically relevant.
The TGA’s Practical Recommendation
The TGA updated prescribing guidance to include a precautionary recommendation for patients using Mounjaro who also rely on oral contraceptive pills. The recommended approach — which mirrors guidance that has appeared in some other countries’ labeling for GLP-1 medications — is straightforward: for a period of four weeks after starting Mounjaro, and for four weeks following each dose increase, patients should use an alternative or additional contraceptive method. The options that satisfy this requirement include:
- Switching entirely to a non-oral contraceptive method during the relevant period, such as a hormonal patch, ring, injection, implant, or intrauterine device
- Adding a barrier method — such as condoms — as supplementary contraception while continuing the oral pill
After the four-week adaptation period at each dose level has passed, patients who have experienced no significant gastrointestinal disturbance may return to relying on oral contraception alone, though they should discuss their individual circumstances with their prescriber. Patients who experience persistent nausea or vomiting — which can themselves affect contraceptive absorption — should discuss their contraceptive strategy with a healthcare provider regardless of the Mounjaro dose adaptation period.
The Pregnancy Warning
The TGA also reiterated guidance that applies across all GLP-1 drugs and reflects the position of regulators in multiple countries: GLP-1 receptor agonist medications should not be used during pregnancy. Animal studies have identified adverse fetal outcomes associated with semaglutide and tirzepatide, and while human data is limited, the precautionary principle supports avoiding these medications during pregnancy until safety in that context is better understood. Patients who are planning a pregnancy should discuss the appropriate timing of GLP-1 medication discontinuation with their prescriber, given that some drugs in this class remain pharmacologically active for weeks after the last dose.
Why International Regulatory Actions Matter for GLP-1 Patients Everywhere
The TGA’s warnings carry significance beyond Australia, both scientifically and legally. International regulatory actions contribute to the global evidence base, create precedents that other regulators consider in their own reviews, and — in the context of pharmaceutical litigation — provide documentation that manufacturers and regulators in other jurisdictions were aware of safety signals that may or may not have been adequately disclosed to patients.
The pattern across the three major regulatory events in the GLP-1 psychiatric safety story is instructive: the EMA acted first with its 2023 formal review; the TGA followed with precautionary prescriber guidance; and the FDA completed its own review in January 2026 without confirming causation. No jurisdiction has yet required a label warning about psychiatric risk for GLP-1 drugs. But the accumulation of regulatory scrutiny — across three independent agencies, on multiple continents, examining the same underlying safety question — is the kind of evidence that plaintiffs’ attorneys will document carefully as the GLP-1 litigation develops.
The failure-to-warn framework that underpins GLP-1 litigation asks not only what the label says, but what the manufacturer knew or should have known — and when. International regulatory reviews, including the TGA’s, contribute to the answer to that question by documenting the global safety discussion that was occurring at specific points in time. For current status on the GLP-1 MDL proceedings, see our GLP-1 litigation status page.
What Patients Should Do With This Information
The practical implications of the TGA’s guidance for patients taking GLP-1 medications fall into two categories depending on which warning is relevant to their circumstances.
Regarding Mental Health Monitoring
Patients should not discontinue their GLP-1 medication based on the TGA’s precautionary psychiatric guidance alone. The warning does not establish that these drugs are causing psychiatric harm, and abrupt discontinuation of a GLP-1 drug — particularly in patients using it for diabetes management — can have its own adverse consequences for metabolic control. What the warning does support is the importance of open communication between patients and their prescribers about mood and mental health throughout the course of GLP-1 treatment. Patients who notice new or worsening depression, unusual anxiety, or any thoughts of self-harm should raise those symptoms with their healthcare provider promptly rather than waiting for a scheduled appointment.
If you are experiencing thoughts of suicide or self-harm right now, please call or text 988 to reach the Suicide and Crisis Lifeline, or text HOME to 741741 for the Crisis Text Line. These services are free, confidential, and available 24 hours a day.
Regarding Oral Contraceptive Use With Mounjaro
Patients who are currently taking Mounjaro and relying on oral contraceptive pills should speak with their prescriber about whether their contraceptive strategy needs to be updated in light of the TGA’s guidance. This is particularly important for patients who are starting Mounjaro for the first time or who are about to increase their dose. The four-week additional contraception recommendation is a practical, low-barrier precaution that eliminates a meaningful risk of unintended pregnancy during a period when contraceptive absorption may be unreliable.
Key Takeaways
For patients, healthcare providers, and legal professionals following the international GLP-1 regulatory landscape, the following points summarize the TGA’s actions and their significance:
- Australia’s TGA issued precautionary mental health monitoring guidance for GLP-1 drugs including Ozempic, Wegovy, Mounjaro, Saxenda, and Trulicity, advising prescribers to monitor patients for depression, suicidal ideation, and mood changes
- The TGA’s Advisory Committee on Medicines concluded that available evidence does not establish a causal relationship between GLP-1 drugs and suicidal behavior — consistent with the EMA’s 2023 conclusion and the FDA’s January 2026 position
- The warnings are precautionary, reflecting the volume of adverse event reports and the complexity of studying psychiatric outcomes in a population with elevated baseline psychiatric risk, not a confirmed finding of drug-induced psychiatric harm
- The TGA also issued a separate warning specific to Mounjaro (tirzepatide), advising that delayed gastric emptying may reduce the absorption and effectiveness of oral contraceptive pills, particularly during treatment initiation and dose escalation
- The TGA’s practical guidance recommends using an alternative or additional contraceptive method for four weeks after starting Mounjaro and four weeks after each dose increase
- GLP-1 medications should not be used during pregnancy, consistent with the guidance of regulators in multiple countries
- The accumulation of international regulatory attention to GLP-1 psychiatric safety — across the EMA, TGA, and FDA — contributes to the evidentiary landscape of the ongoing GLP-1 litigation even though no jurisdiction has confirmed causation or required a psychiatric warning label
The TGA’s precautionary stance is a measured regulatory response to a genuine scientific uncertainty. It does not resolve the question of whether GLP-1 drugs affect mental health, and it is not intended to. What it does is ensure that the uncertainty is actively managed in clinical practice — that prescribers are alert to psychiatric symptoms in their GLP-1 patients, that patients know to report mood changes, and that the adverse event data necessary to eventually answer the causation question continues to accumulate. That is how post-market drug safety surveillance is supposed to work.